Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PF-06446846
i
Other names:
PF-06446846, PF846, PF06446846, PF-846, PF 06446846, PF 846
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Pfizer
Drug class:
PCSK9 inhibitor
Related drugs:
‹
evolocumab (1)
ongericimab (0)
alirocumab (0)
evolocumab (1)
ongericimab (0)
alirocumab (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PCSK9 expression
Ovarian Cancer
PCSK9 expression
Ovarian Cancer
PF-06446846
Sensitive: D – Preclinical
PF-06446846
Sensitive
:
D
PF-06446846
Sensitive: D – Preclinical
PF-06446846
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.